<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265824</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000453861</org_study_id>
    <secondary_id>GERCOR-C04-2</secondary_id>
    <secondary_id>EU-20565</secondary_id>
    <secondary_id>GERCOR-OPTIMOX3</secondary_id>
    <secondary_id>GERCOR-DREAM- C04-2</secondary_id>
    <nct_id>NCT00265824</nct_id>
  </id_info>
  <brief_title>Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)</brief_title>
  <acronym>DREAM</acronym>
  <official_title>Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab&#xD;
      alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work&#xD;
      compared to maintenance therapy with bevacizumab+erlotinib alone after an induction therapy&#xD;
      combining bevacizumab+chemotherapy in treating patients with metastatic colorectal cancer&#xD;
      that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare Progression-free survival during maintenance period (&quot;Maintenance PFS&quot;)in&#xD;
           patients with unresectable metastatic colorectal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the duration of disease control and overall survival of patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Compare the tolerability of these regimens in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the occurrence of secondary surgery in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the chemotherapy-free intervals and response rates in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
      INDUCTION THERAPY&#xD;
&#xD;
      Bevacizumab IV over 30-90 minutes on day 1, combined with either:&#xD;
&#xD;
        -  modified FOLFOX7 (IV : oxaliplatin, folinic acid, fluorouracil),&#xD;
&#xD;
        -  XELOX2 (IV : oxaliplatin, oral capecitabine day 1 to 8),&#xD;
&#xD;
        -  FOLFIRI (IV : irinotecan, folinic acid, fluorouracil).&#xD;
&#xD;
      Treatment repeats every 2 weeks.&#xD;
&#xD;
      RANDOMIZATION Patients with stable or responding disease then receive maintenance therapy&#xD;
      with bevacizumab alone or bevacizumab+erlotinib&#xD;
&#xD;
      MAINTENANCE THERAPY&#xD;
&#xD;
        -  Arm A : bevacizumab alone : bevacizumab IV over 30-90 minutes on day 1&#xD;
&#xD;
        -  Arm B : bevacizumab+erlotinib : bevacizumab IV over 30-90 minutes on day 1 and oral&#xD;
           erlotinib once daily on days 1-21.&#xD;
&#xD;
      In both arms, treatment with bevacizumab +/- erlotinib repeats every 3 weeks in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ACCRUAL: A total of 700 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival during maintenance therapy</measure>
    <time_frame>Tumor evaluation every 2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>bevacizumab alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity</description>
    <arm_group_label>bevacizumab alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab, erlotinib</intervention_name>
    <description>bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity</description>
    <arm_group_label>Bevacizumab + erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MAIN ELIGIBILITY CRITERIA&#xD;
&#xD;
          -  Histologically proven metastatic adenocarcinoma of colon or rectum&#xD;
&#xD;
          -  Documented inoperable disease (i.e., not suitable for complete carcinological surgical&#xD;
             resection)&#xD;
&#xD;
          -  Measurable lesion as assessed by CT scan or MRI in at least one dimension (longest&#xD;
             diameter to be recorded) ≥ 20 mm with conventional CT scan or ≥ 10 mm with spiral CT&#xD;
             scan&#xD;
&#xD;
          -  No previous therapy for metastatic disease&#xD;
&#xD;
          -  No history or evidence upon physical examination of CNS disease (e.g., non-irradiated&#xD;
             CNS metastasis, seizure not controlled with standard medical therapy, or history of&#xD;
             stroke) unless adequately treated&#xD;
&#xD;
          -  No exclusive bone metastasis&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL (may be transfused to maintain or exceed this level)&#xD;
&#xD;
          -  Proteinuria &lt; 2+ by dipstick OR ≤ 1 g of protein on 24-hr urine collection&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 3 times ULN&#xD;
&#xD;
          -  No peripheral sensory neuropathy&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective means of contraception (oral contraceptives,&#xD;
             intrauterine contraceptive device, barrier method of contraception in conjunction with&#xD;
             spermicidal jelly, or surgically sterilization)&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 1&#xD;
&#xD;
          -  No clinically significant (i.e. active) cardiovascular disease&#xD;
&#xD;
          -  No evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No significant ophthalmologic abnormality&#xD;
&#xD;
          -  More than 28 days since prior major surgical procedure or open biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimery de Gramont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Saint Antoine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Tournigand, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Henri Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Steyr</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Universitätsklinik für Innere Medizin I</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cité de la Santé de Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mc Gill University Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles LeMoyne</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Antibes</city>
        <zip>06606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Auxerre</city>
        <zip>89011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Beauvais</city>
        <zip>60000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Briey</city>
        <zip>54140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Drevon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD les oudairies</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>F-72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la sauvegarde</name>
      <address>
        <city>Lyon</city>
        <zip>69009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institu Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Claude BERNARD</name>
      <address>
        <city>Metz</city>
        <zip>57070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Layné</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Le Raincy - Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier les Diaconnesses</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre Catalan oncologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Semur en Auxois</city>
        <zip>21140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Générale</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

